Paying for innovation: Reimbursement incentives for antibiotics

Science Translational Medicine

Volumn 7, Issue 276, 2015, Pages

  Hwang, Thomas J ^a,b   Carpenter, Daniel ^a,c   Kesselheim, Aaron S ^d  

^a HARVARD UNIVERSITY   (United States)

^b Blackstone Group   (United Kingdom)

^c HARVARD UNIVERSITY   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; COLISTIN; FIDAXOMICIN; PLAZOMICIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL PNEUMONIA; BLOODSTREAM INFECTION; DRUG APPROVAL; DRUG MARKETING; DRUG USE; FUNDING; HEALTH CARE POLICY; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; OTITIS MEDIA; PEPTOCLOSTRIDIUM DIFFICILE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REIMBURSEMENT; SHORT SURVEY; ECONOMICS; HOSPITAL PATIENT; INVENTION;

ANTI-BACTERIAL AGENTS; HEALTH POLICY; HUMANS; INPATIENTS; INVENTIONS; REIMBURSEMENT, INCENTIVE;

EID: 84923875606     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aaa1429     Document Type: Short Survey

References (10)

1. T. J. Hwang, D. Carpenter, A. S. Kesselheim, Target small firms for antibiotic innovation. Science 344, 967-969 (2014).
2. President's Council of Advisors on Science and Technology, Report to the President on Combating Antibiotic Resistance. Executive Office of the President (2014).
3. A. S. Kesselheim, Y. T. Tan, J. Avorn, The roles of academia, rare diseases, and repurposing in the development of the most transformative drugs. Health Af. 34, 286-293 (2015).
4. R. Kocher, B. Roberts, The calculus of cures. N. Engl. J. Med. 370, 1473-1475 (2014).
5. S. R. Norrby, C. E. Nord, R. Finch, Lack of development of new antimicrobial drugs: A potential serious threat to public health. Lancet Infect. Dis. 5, 115-119 (2005).
6. Eastern Research Group (ERG), Analytical Framework for Examining the Value of Antibacterial Products (ERG, Lexington, MA, 2014).
7. T. A. Brennan, J. M. Wilson, The special case of gene therapy pricing. Nat. Biotechnol. 32, 874-876 (2014).
8. A. T. Clyde, L. Bockstedt, J. A. Farkas, C. Jackson, Experience with Medicare's new technology add-on payment program. Health Af. 27, 1632-1641 (2008).
9. B. Wang, J. Liu, A. S. Kesselheim, Variations in time of market exclusivity among top-selling prescription drugs in the United States. J. Am. Med. Assoc. Int. Med., published online February 9, 2015.10.1001/jamainternmed.2014.7968
10. Infectious Diseases Society of America, White paper: Recommendations on the conduct of superiority and orga nism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens. Clin. Infect. Dis. 55, 1031-1046 (2012).